{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T18:31:55Z","timestamp":1788201115027,"version":"build-2803163510"},"reference-count":104,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Metastasis Rev"],"DOI":"10.1007\/s10555-025-10261-7","type":"journal-article","created":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T14:21:13Z","timestamp":1745418073000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["CAR T-cells for acute leukemias in children: current status, challenges, and future directions"],"prefix":"10.1007","volume":"44","author":[{"given":"Marie Emilie","family":"Dourthe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Baruchel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,23]]},"reference":[{"issue":"9967","key":"10261_CR1","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","volume":"385","author":"DW Lee","year":"2015","unstructured":"Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., et al. (2015). T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose-escalation trial. Lancet Lond. Engl., 385(9967), 517\u2013528.","journal-title":"Lancet Lond. Engl."},{"issue":"15","key":"10261_CR2","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1200\/JCO.20.02262","volume":"39","author":"NN Shah","year":"2021","unstructured":"Shah, N. N., Lee, D. W., Yates, B., et al. (2021). Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL. Journal of Clinical Oncology, 39(15), 1650\u20131659. https:\/\/doi.org\/10.1200\/JCO.20.02262","journal-title":"Journal of Clinical Oncology"},{"issue":"25","key":"10261_CR3","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","volume":"129","author":"RA Gardner","year":"2017","unstructured":"Gardner, R. A., Finney, O., Annesley, C., et al. (2017). Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood, 129(25), 3322\u20133331.","journal-title":"Blood"},{"issue":"4","key":"10261_CR4","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/sj.leu.2403302","volume":"18","author":"C Imai","year":"2004","unstructured":"Imai, C., Mihara, K., Andreansky, M., et al. (2004). Chimeric receptors with 4\u20131BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia, 18(4), 676\u2013684.","journal-title":"Leukemia"},{"issue":"16","key":"10261_CR5","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude, S. L., Frey, N., Shaw, P. A., et al. (2014). Chimeric antigen receptor T cells for sustained remissions in leukemia. New England Journal of Medicine, 371(16), 1507\u20131517.","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10261_CR6","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude, S. L., Laetsch, T. W., Buechner, J., et al. (2018). Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. New England Journal of Medicine, 378(5), 439\u2013448.","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10261_CR7","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1200\/JCO.22.00642","volume":"41","author":"TW Laetsch","year":"2022","unstructured":"Laetsch, T. W., Maude, S. L., Rives, S., et al. (2022). Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA Trial. Journal Clinical Oncology, 41(9), 1664\u20131669. https:\/\/doi.org\/10.1200\/JCO.22.00642","journal-title":"Journal Clinical Oncology."},{"issue":"26","key":"10261_CR8","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1182\/blood.2019001641","volume":"134","author":"KJ Curran","year":"2019","unstructured":"Curran, K. J., Margossian, S. P., Kernan, N. A., et al. (2019). Toxicity and response after CD19-specific CAR T-cell therapy in pediatric\/young adult relapsed\/refractory B-ALL. Blood, 134(26), 2361\u20132368.","journal-title":"Blood"},{"issue":"9","key":"10261_CR9","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1038\/s41591-019-0549-5","volume":"25","author":"S Ghorashian","year":"2019","unstructured":"Ghorashian, S., Kramer, A. M., Onuoha, S., et al. (2019). Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. Nature Medicine, 25(9), 1408\u20131414.","journal-title":"Nature Medicine"},{"issue":"3","key":"10261_CR10","doi-asserted-by":"publisher","first-page":"747","DOI":"10.3324\/haematol.2022.280678","volume":"108","author":"AS Wayne","year":"2023","unstructured":"Wayne, A. S., Huynh, V., Hijiya, N., et al. (2023). Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed\/refractory acute lymphoblastic leukemia. Haematologica, 108(3), 747\u2013760.","journal-title":"Haematologica"},{"issue":"23","key":"10261_CR11","first-page":"01420","volume":"S2666\u20136367","author":"RM Myers","year":"2023","unstructured":"Myers, R. M., Jacoby, E., Pulsipher, M. A., et al. (2023). Clinical variables associated with improved outcomes for children and young adults treated with CAR T cells for B-ALL: A decade of CAR translation. Transplant Cell Theraphy, S2666\u20136367(23), 01420\u201301423.","journal-title":"Transplant Cell Theraphy"},{"issue":"9","key":"10261_CR12","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1200\/JCO.21.01405","volume":"40","author":"RM Myers","year":"2021","unstructured":"Myers, R. M., Taraseviciute, A., Steinberg, S. M., et al. (2021). Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL. Journal Clinical Oncology, 40(9), 932\u2013944. https:\/\/doi.org\/10.1200\/JCO.21.01405","journal-title":"Journal Clinical Oncology."},{"issue":"Supplement 1","key":"10261_CR13","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1182\/blood-2020-134472","volume":"136","author":"LM Schultz","year":"2020","unstructured":"Schultz, L. M., Baggott, C., Prabhu, S., et al. (2020). Disease burden impacts outcomes in pediatric and young adult B-cell acute lymphoblastic leukemia after commercial tisagenlecleucel: Results from the Pediatric Real World CAR Consortium (PRWCC). Blood, 136(Supplement 1), 14\u201315.","journal-title":"Blood"},{"issue":"Supplement_1","key":"10261_CR14","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1182\/blood-2019-129279","volume":"134","author":"S Grupp","year":"2019","unstructured":"Grupp, S., Hu, Z.-H., Zhang, Y., et al. (2019). Tisagenlecleucel chimeric antigen receptor (CAR) T-cell therapy for relapsed\/refractory children and young adults with acute lymphoblastic leukemia (ALL): Real world experience from the Center for International Blood and Marrow Transplant Research (CIBMTR) and Cellular Therapy (CT) Registry. Blood, 134(Supplement_1), 2619\u20132619.","journal-title":"Blood"},{"issue":"12","key":"10261_CR15","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1038\/s41375-021-01281-7","volume":"35","author":"M-E Dourthe","year":"2021","unstructured":"Dourthe, M.-E., Rabian, F., Yakouben, K., et al. (2021). Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia. Leukemia, 35(12), 3383\u20133393.","journal-title":"Leukemia"},{"issue":"10","key":"10261_CR16","doi-asserted-by":"publisher","first-page":"e766","DOI":"10.1016\/S2352-3026(22)00225-3","volume":"9","author":"S Ghorashian","year":"2022","unstructured":"Ghorashian, S., Jacoby, E., De Moerloose, B., et al. (2022). Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: An international, multicentre, retrospective cohort study. Lancet Haematol., 9(10), e766\u2013e775.","journal-title":"Lancet Haematol."},{"issue":"3","key":"10261_CR17","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s00262-021-03009-z","volume":"71","author":"X Zhang","year":"2022","unstructured":"Zhang, X., Yang, J., Li, J., et al. (2022). Factors associated with treatment response to CD19 CAR-T therapy among a large cohort of B cell acute lymphoblastic leukemia. Cancer Immunology Immunotherapy CII, 71(3), 689\u2013703.","journal-title":"Cancer Immunology Immunotherapy CII"},{"issue":"14","key":"10261_CR18","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1182\/blood.2021012727","volume":"139","author":"AB Leahy","year":"2021","unstructured":"Leahy, A. B., Devine, K. J., Li, Y., et al. (2021). Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy. Blood, 139(14), 2173\u20132185. https:\/\/doi.org\/10.1182\/blood.2021012727","journal-title":"Blood"},{"issue":"11","key":"10261_CR19","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1182\/bloodadvances.2022008981","volume":"7","author":"P Bader","year":"2023","unstructured":"Bader, P., Rossig, C., Hutter, M., et al. (2023). CD19 CAR T cells are an effective therapy forposttransplant relapse in patients with B-lineage ALL: real-world data from Germany. Blood Advances, 7(11), 2436\u20132448. https:\/\/doi.org\/10.1182\/bloodadvances.2022008981","journal-title":"Blood Advances."},{"issue":"22","key":"10261_CR20","doi-asserted-by":"publisher","first-page":"3539","DOI":"10.1182\/bloodadvances.2019000692","volume":"3","author":"V Pillai","year":"2019","unstructured":"Pillai, V., Muralidharan, K., Meng, W., et al. (2019). CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy. Blood Advances, 3(22), 3539\u20133549.","journal-title":"Blood Advances"},{"key":"10261_CR21","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1182\/blood-2021-148820","volume":"138","author":"K Mullanfiroze","year":"2021","unstructured":"Mullanfiroze, K., Ottaviano, G., Mishra, A. K., et al. (2021). Outcomes of children and young adults with acute lymphoblastic leukaemia administered inotuzumab Pre CAR-T therapy. Blood, 138, 1743.","journal-title":"Blood"},{"issue":"1","key":"10261_CR22","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41375-022-01740-9","volume":"37","author":"V Ceolin","year":"2022","unstructured":"Ceolin, V., Brivio, E., van Tinteren, H., et al. (2022). Outcome of chimeric antigen receptor T-cell therapy following treatment with inotuzumab ozogamicin in children with relapsed or refractory acute lymphoblastic leukemia. Leukemia, 37(1), 53\u201360. https:\/\/doi.org\/10.1038\/s41375-022-01740-9","journal-title":"Leukemia"},{"issue":"2","key":"10261_CR23","doi-asserted-by":"publisher","first-page":"72.e1","DOI":"10.1016\/j.jtct.2021.11.014","volume":"28","author":"S Shahid","year":"2022","unstructured":"Shahid, S., Ramaswamy, K., Flynn, J., et al. (2022). Impact of bridging chemotherapy on clinical outcoMES of CD19-specific CAR T cell therapy in children\/young adults with relapsed\/refractory B cell acute lymphoblastic leukemia. Transplant and Cellular Theraphy, 28(2), 72.e1-72.e8.","journal-title":"Transplant and Cellular Theraphy"},{"key":"10261_CR24","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1182\/blood-2023-175045","volume":"142","author":"N Lecornec","year":"2023","unstructured":"Lecornec, N., Dourthe, M.-E., Rabian, F., et al. (2023). Low disease burden pre-CAR-T cell therapy for children and AYA with B-ALL is associated with an impaired outcome when obtained through intensification of the bridging therapy. Blood, 142, 2134.","journal-title":"Blood"},{"issue":"27","key":"10261_CR25","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.1200\/JCO.20.03458","volume":"39","author":"RM Myers","year":"2021","unstructured":"Myers, R. M., Li, Y., Barz Leahy, A., et al. (2021). Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 39(27), 3044\u20133055. https:\/\/doi.org\/10.1200\/JCO.20.03458","journal-title":"Journal of Clinical Oncology."},{"issue":"2","key":"10261_CR26","doi-asserted-by":"publisher","first-page":"73.e1","DOI":"10.1016\/j.jtct.2021.11.019","volume":"28","author":"JW Ravich","year":"2021","unstructured":"Ravich, J. W., Huang, S., Zhoum, Y., et al. (2021). Impact of High Disease Burden on Survival in Pediatric Patients with B-ALL Treated with Tisagenlecleucel. Transplant Cellular Theraphy, 28(2), 73.e1-73.e9. https:\/\/doi.org\/10.1016\/j.jtct.2021.11.019","journal-title":"Transplant Cellular Theraphy"},{"issue":"10","key":"10261_CR27","doi-asserted-by":"publisher","first-page":"e711","DOI":"10.1016\/S2352-3026(21)00238-6","volume":"8","author":"AB Leahy","year":"2021","unstructured":"Leahy, A. B., Newman, H., Li, Y., et al. (2021). CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: A post-hoc analysis of pooled data from five clinical trials. Lancet Haematol., 8(10), e711\u2013e722.","journal-title":"Lancet Haematol."},{"issue":"2","key":"10261_CR28","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.ymthe.2020.09.027","volume":"29","author":"V Ort\u00edz-Maldonado","year":"2021","unstructured":"Ort\u00edz-Maldonado, V., Rives, S., Castell\u00e0, M., et al. (2021). CART19-BE-01: A multicenter trial of ARI-0001 cell therapy in patients with CD19+ relapsed\/refractory malignancies. Molecular Theraphy Journal of the American Society of Gene Theraphy, 29(2), 636\u2013644.","journal-title":"Molecular Theraphy Journal of the American Society of Gene Theraphy"},{"issue":"6","key":"10261_CR29","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1038\/s41375-022-01546-9","volume":"36","author":"E Jacoby","year":"2022","unstructured":"Jacoby, E., Ghorashian, S., Vormoor, B., et al. (2022). CD19 CAR T-cells for pediatric relapsed acute lymphoblastic leukemia with active CNS involvement: A retrospective international study. Leukemia, 36(6), 1525\u20131532.","journal-title":"Leukemia"},{"issue":"2","key":"10261_CR30","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1182\/bloodadvances.2021005564","volume":"6","author":"VA Fabrizio","year":"2022","unstructured":"Fabrizio, V. A., Phillips, C. L., Lane, A., et al. (2022). Tisagenlecleucel outcomes in relapsed\/refractory extramedullary ALL: A Pediatric Real World CAR Consortium Report. Blood Advances, 6(2), 600\u2013610.","journal-title":"Blood Advances"},{"issue":"Supplement 1","key":"10261_CR31","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1182\/blood-2018-99-115460","volume":"132","author":"MA Pulsipher","year":"2018","unstructured":"Pulsipher, M. A., Han, X., Quigley, M., et al. (2018). Molecular detection of minimal residual disease precedes morphological relapse and could be used to identify relapse in pediatric and young adult B-cell acute lymphoblastic leukemia patients treated with tisagenlecleucel. Blood, 132(Supplement 1), 1551\u20131551.","journal-title":"Blood"},{"issue":"11","key":"10261_CR32","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1182\/blood.2022016937","volume":"141","author":"RM Myers","year":"2022","unstructured":"Myers, R. M., Shah, N. N., & Pulsipher, M. A. (2022). How I use risk factors for success or failure of CD19 CAR T cells to guide management of children and AYA with B-cell ALL. Blood, 141(11), 1251\u20131264. https:\/\/doi.org\/10.1182\/blood.2022016937","journal-title":"Blood."},{"issue":"11","key":"10261_CR33","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.jtct.2023.08.030","volume":"29","author":"AJ Lamble","year":"2023","unstructured":"Lamble, A. J., Moskop, A., Pulsipher, M. A., et al. (2023). INSPIRED symposium part 2: Prevention and management of relapse following chimeric antigen receptor T Cell therapy for B cell acute lymphoblastic leukemiA. Transplant. Cell. Ther., 29(11), 674\u2013684.","journal-title":"Transplant. Cell. Ther."},{"issue":"3","key":"10261_CR34","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.ymthe.2024.02.016","volume":"32","author":"N Singh","year":"2024","unstructured":"Singh, N. (2024). Analysis of pre-treatment tumors reveals gatekeepers of response to CAR T cells. Molecular Theraphy Journal of American Society Gene Theraphy, 32(3), 567\u2013568.","journal-title":"Molecular Theraphy Journal of American Society Gene Theraphy"},{"issue":"9","key":"10261_CR35","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1158\/2159-8290","volume":"11","author":"GM Chen","year":"2021","unstructured":"Chen, G. M., Chen, C., Das, R. K., et al. (2021). Integrative Bulk and Single-Cell Profiling of Premanufacture T-cell Populations Reveals Factors Mediating Long-Term Persistence of CAR T-cell Therapy. Cancer Discovery, 11(9), 2186\u20132199. https:\/\/doi.org\/10.1158\/2159-8290","journal-title":"Cancer Discovery"},{"issue":"7897","key":"10261_CR36","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","volume":"602","author":"JJ Melenhorst","year":"2022","unstructured":"Melenhorst, J. J., Chen, G. M., Wang, M., et al. (2022). Decade-long leukaemia remissions with persistence of CD4+ CAR T cells. Nature, 602(7897), 503\u2013509.","journal-title":"Nature"},{"issue":"1","key":"10261_CR37","doi-asserted-by":"publisher","first-page":"8048","DOI":"10.1038\/s41467-023-43790-2","volume":"14","author":"A Ramos","year":"2023","unstructured":"Ramos, A., Koch, C. E., Liu-Lupo, Y., et al. (2023). Leukemia-intrinsic determinants of CAR-T response revealed by iterative in vivo genome-wide CRISPR screening. Nature Communications, 14(1), 8048.","journal-title":"Nature Communications"},{"issue":"7","key":"10261_CR38","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1038\/s41591-023-02415-3","volume":"29","author":"ND Anderson","year":"2023","unstructured":"Anderson, N. D., Birch, J., Accogli, T., et al. (2023). Transcriptional signatures associated with persisting CD19 CAR-T cells in children with leukemia. Nature Medicine, 29(7), 1700\u20131709. https:\/\/doi.org\/10.1038\/s41591-023-02415-3","journal-title":"Nature Medicine"},{"issue":"2","key":"10261_CR39","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1158\/2643-3230.BCD-23-0212","volume":"5","author":"NJ Haradhvala","year":"2024","unstructured":"Haradhvala, N. J., & Maus, M. V. (2024). Understanding mechanisms of response to CAR T-cell therapy through single-cell sequencing: Insights and challenges. Blood Cancer Discov., 5(2), 86\u201389.","journal-title":"Blood Cancer Discov."},{"issue":"7949","key":"10261_CR40","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","volume":"614","author":"L Labanieh","year":"2023","unstructured":"Labanieh, L., & Mackall, C. L. (2023). CAR immune cells: Design principles, resistance and the next generation. Nature, 614(7949), 635\u2013648.","journal-title":"Nature"},{"key":"10261_CR41","doi-asserted-by":"crossref","unstructured":"Bai, Z., Woodhouse, S., Zhao, Z., et al. (2022) Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALL. Sciences Advance. 8(23):eabj2820.","DOI":"10.1126\/sciadv.abj2820"},{"issue":"1","key":"10261_CR42","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41591-018-0290-5","volume":"25","author":"J Feucht","year":"2019","unstructured":"Feucht, J., Sun, J., Eyquem, J., et al. (2019). Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency. Nature Medicine, 25(1), 82\u201388.","journal-title":"Nature Medicine"},{"issue":"5","key":"10261_CR43","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1158\/2159-8290.CD-19-0945","volume":"10","author":"RG Majzner","year":"2020","unstructured":"Majzner, R. G., Rietberg, S. P., Sotillo, E., et al. (2020). Tuning the antigen density requirement for CAR T-cell activity. Cancer Discovery, 10(5), 702\u2013723.","journal-title":"Cancer Discovery"},{"issue":"7786","key":"10261_CR44","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41586-019-1805-z","volume":"576","author":"RC Lynn","year":"2019","unstructured":"Lynn, R. C., Weber, E. W., Sotillo, E., et al. (2019). c-Jun overexpression in CAR T cells induces exhaustion resistance. Nature, 576(7786), 293\u2013300.","journal-title":"Nature"},{"issue":"8","key":"10261_CR45","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/s41590-021-00964-8","volume":"22","author":"H Seo","year":"2021","unstructured":"Seo, H., Gonz\u00e1lez-Avalos, E., Zhang, W., et al. (2021). BATF and IRF4 cooperate to counter exhaustion in tumor-infiltrating CAR T cells. Nature Immunology, 22(8), 983\u2013995. https:\/\/doi.org\/10.1038\/s41590-021-00964-8","journal-title":"Nature Immunology"},{"issue":"6537","key":"10261_CR46","doi-asserted-by":"publisher","first-page":"eaba1786","DOI":"10.1126\/science.aba1786","volume":"372","author":"EW Weber","year":"2021","unstructured":"Weber, E. W., Parker, K. R., Sotillo, E., et al. (2021). Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling. Science, 372(6537), eaba1786. https:\/\/doi.org\/10.1126\/science.aba1786","journal-title":"Science"},{"key":"10261_CR47","doi-asserted-by":"crossref","unstructured":"Stadtmauer, E. A., Fraietta, J. A., Davis, M. M., et al. (2020) CRISPR-engineered T cells in patients with refractory cancer. Science. 367(6481):eaba7365.","DOI":"10.1126\/science.aba7365"},{"issue":"9","key":"10261_CR48","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1158\/2159-8290.CD-22-1276","volume":"13","author":"MJ Dickinson","year":"2023","unstructured":"Dickinson, M. J., Barba, P., J\u00e4ger, U., et al. (2023). A novel autologous CAR-T therapy, YTB323, with preserved T-cell stemness shows enhanced CAR T-cell efficacy in preclinical and early clinical development. Cancer Discovery, 13(9), 1982\u20131997.","journal-title":"Cancer Discovery"},{"issue":"Supplement 1","key":"10261_CR49","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1182\/blood-2022-162520","volume":"140","author":"P Barba","year":"2022","unstructured":"Barba, P., Kwon, M., Briones, J., et al. (2022). YTB323 (Rapcabtagene Autoleucel) demonstrates durable efficacy and a manageable safety profile in patients with relapsed\/refractory diffuse large B-cell lymphoma: Phase I study update. Blood, 140(Supplement 1), 1056\u20131059.","journal-title":"Blood"},{"issue":"7","key":"10261_CR50","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1182\/bloodadvances.2021006418","volume":"6","author":"VA Fabrizio","year":"2022","unstructured":"Fabrizio, V. A., Boelens, J. J., Mauguen, A., et al. (2022). Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy. Blood Advances, 6(7), 1961\u20131968.","journal-title":"Blood Advances"},{"issue":"7","key":"10261_CR51","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1182\/bloodadvances.2021006700","volume":"6","author":"L Dekker","year":"2022","unstructured":"Dekker, L., Calkoen, F. G., Jiang, Y., et al. (2022). Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia. Blood Advances, 6(7), 1969\u20131976.","journal-title":"Blood Advances"},{"issue":"9","key":"10261_CR52","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1182\/bloodadvances.2024012885","volume":"8","author":"RM Myers","year":"2024","unstructured":"Myers, R. M., Devine, K. J., Li, Y., et al. (2024). Reinfusion of CD19 CAR T cells for relapse prevention and treatment in children with acute lymphoblastic leukemia. Blood Advance, 8(9), 2182\u20132192. https:\/\/doi.org\/10.1182\/bloodadvances.2024012885","journal-title":"Blood Advance"},{"issue":"15","key":"10261_CR53","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1200\/JCO.2017.35.15_suppl.103","volume":"35","author":"SL Maude","year":"2017","unstructured":"Maude, S. L., Hucks, G. E., Seif, A. E., et al. (2017). The effect of pembrolizumab in combination with CD19-targeted chimeric antigen receptor (CAR) T cells in relapsed acute lymphoblastic leukemia (ALL). Journal of Clinical Oncology, 35(15), 103\u2013103.","journal-title":"Journal of Clinical Oncology"},{"issue":"22","key":"10261_CR54","first-page":"00245","volume":"S2352\u20133026","author":"R Benjamin","year":"2022","unstructured":"Benjamin, R., Jain, N., Maus, M. V., et al. (2022). UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): A phase 1, dose-escalation trial. Lancet Haematol, S2352\u20133026(22), 00245\u201300249.","journal-title":"Lancet Haematol"},{"key":"10261_CR55","doi-asserted-by":"crossref","unstructured":"Ottaviano, G., Georgiadis, C., Gkazi, S. A., et al. (2022) Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia. Science Translate Medicine. 14(668):eabq3010.","DOI":"10.1126\/scitranslmed.abq3010"},{"issue":"1","key":"10261_CR56","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1111\/bjh.19524","volume":"205","author":"ME Dourthe","year":"2024","unstructured":"Dourthe, M. E., Yakouben, K., David, A., et al. (2024). Success of donor-derived CAR-T cells after failure of autologous CD19 CAR-T cells (tisagenlecleucel) in B-cell acute lymphoblastic leukaemia. British Journal of Haematology, 205(1), 373\u2013377.","journal-title":"British Journal of Haematology"},{"issue":"2","key":"10261_CR57","first-page":"146","volume":"142","author":"F Del Bufalo","year":"2023","unstructured":"Del Bufalo, F., Becilli, M., Rosignoli, C., et al. (2023). Allogeneic, donor-derived, second-generation, CD19-directed CAR-T cells for the treatment of pediatric relapsed\/refractory BCP-ALL. Blood, 142(2), 146\u2013157.","journal-title":"Blood"},{"key":"10261_CR58","doi-asserted-by":"publisher","first-page":"103807","DOI":"10.1016\/j.critrevonc.2022.103807","volume":"179","author":"S Chen","year":"2022","unstructured":"Chen, S., Zhang, Y., Fang, C., et al. (2022). Donor-derived and off-the-shelf allogeneic anti-CD19 CAR T-cell therapy for R\/R ALL and NHL: A systematic review and meta-analysis. Critical Review in Oncology Hematology, 179, 103807. https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103807","journal-title":"Critical Review in Oncology Hematology"},{"issue":"6","key":"10261_CR59","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1097\/MOH.0000000000000685","volume":"28","author":"M Qayed","year":"2021","unstructured":"Qayed, M., Bleakley, M., & Shah, N. N. (2021). Role of chimeric antigen receptor T-cell therapy: Bridge to transplantation or stand-alone therapy in pediatric acute lymphoblastic leukemia. Current Opinion in Hematology, 28(6), 373\u2013379.","journal-title":"Current Opinion in Hematology"},{"issue":"8","key":"10261_CR60","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1182\/bloodadvances.2023011168","volume":"8","author":"M Gabelli","year":"2023","unstructured":"Gabelli, M., Oporto-Espuelas, M., Bonney, D. K., et al. (2023). Maintenance therapy for early loss of B-cell aplasia after anti-CD19 CAR T-cell therapy. Blood Advances, 8(8), 1959\u20131963. https:\/\/doi.org\/10.1182\/bloodadvances.2023011168","journal-title":"Blood Advances. bloodadvances."},{"issue":"9","key":"10261_CR61","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1200\/JCO.22.02345","volume":"41","author":"RA Gardner","year":"2023","unstructured":"Gardner, R. A., & Shah, N. N. (2023). CAR T-Cells for Cure in Pediatric B-ALL. Journal of Clinical Oncoogyl, 41(9), 1646\u20131648. https:\/\/doi.org\/10.1200\/JCO.22.02345","journal-title":"Journal of Clinical Oncoogyl"},{"issue":"1","key":"10261_CR62","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jtct.2021.10.003","volume":"28","author":"C Summers","year":"2022","unstructured":"Summers, C., Wu, Q. V., Annesley, C., et al. (2022). Hematopoietic cell transplantation after CD19 chimeric antigen receptor T cell-induced acute lymphoblastic lymphoma remission confers a leukemia-free survival advantage. Transplant. Cell. Ther., 28(1), 21\u201329.","journal-title":"Transplant. Cell. Ther."},{"issue":"12","key":"10261_CR63","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","volume":"5","author":"E Sotillo","year":"2015","unstructured":"Sotillo, E., Barrett, D. M., Black, K. L., et al. (2015). Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discovery, 5(12), 1282\u20131295.","journal-title":"Cancer Discovery"},{"issue":"10","key":"10261_CR64","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","volume":"24","author":"EJ Orlando","year":"2018","unstructured":"Orlando, E. J., Han, X., Tribouley, C., et al. (2018). Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nature Medicine, 24(10), 1504\u20131506.","journal-title":"Nature Medicine"},{"issue":"1","key":"10261_CR65","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/s41467-021-21168-6","volume":"12","author":"T Rabilloud","year":"2021","unstructured":"Rabilloud, T., Potier, D., Pankaew, S., et al. (2021). Single-cell profiling identifies pre-existing CD19-negative subclones in a B-ALL patient with CD19-negative relapse after CAR-T therapy. Nature Communications, 12(1), 865.","journal-title":"Nature Communications"},{"issue":"1","key":"10261_CR66","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1182\/blood.2022016335","volume":"140","author":"NN Shah","year":"2022","unstructured":"Shah, N. N., & Fry, T. J. (2022). The CD19neg needle in the haystack. Blood, 140(1), 4\u20136.","journal-title":"Blood"},{"key":"10261_CR67","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1182\/blood-2021-151002","volume":"138","author":"P Domizi","year":"2021","unstructured":"Domizi, P., Sarno, J., Jager, A., et al. (2021). Ikaros mediates antigen escape following CD19 CAR T cell therapy in r\/r B-ALL. Blood, 138, 613.","journal-title":"Blood"},{"issue":"17","key":"10261_CR68","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1200\/JCO.19.03279","volume":"38","author":"NN Shah","year":"2020","unstructured":"Shah, N. N., Highfill, S. L., Shalabi, H., et al. (2020). CD4\/CD8 T-cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: Updated results from a phase I anti-CD22 CAR T-cell trial. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol., 38(17), 1938\u20131950.","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"10","key":"10261_CR69","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1038\/s41591-021-01497-1","volume":"27","author":"S Cordoba","year":"2021","unstructured":"Cordoba, S., Onuoha, S., Thomas, S., et al. (2021). CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: A phase 1 trial. Nature Medicine, 27(10), 1797\u20131805.","journal-title":"Nature Medicine"},{"issue":"Supplement_1","key":"10261_CR70","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1182\/blood-2019-129411","volume":"134","author":"LM Schultz","year":"2019","unstructured":"Schultz, L. M., Muffly, L. S., Spiegel, J. Y., et al. (2019). Phase I trial using CD19\/CD22 bispecific CAR T cells in pediatric and adult acute lymphoblastic leukemia (ALL). Blood, 134(Supplement_1), 744\u2013744.","journal-title":"Blood"},{"issue":"11","key":"10261_CR71","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/S1470-2045(23)00436-9","volume":"24","author":"J Pan","year":"2023","unstructured":"Pan, J., Tang, K., Luo, Y., et al. (2023). Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: A single-arm, phase 2 study. The lancet Oncology, 24(11), 1229\u20131241.","journal-title":"The lancet Oncology"},{"issue":"5","key":"10261_CR72","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1182\/blood.2019003293","volume":"135","author":"J Pan","year":"2020","unstructured":"Pan, J., Zuo, S., Deng, B., et al. (2020). Sequential CD19-22 CAR T therapy induces sustained remission in children with r\/r B-ALL. Blood, 135(5), 387\u2013391.","journal-title":"Blood"},{"issue":"9","key":"10261_CR73","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1200\/JCO.22.01214","volume":"41","author":"T Wang","year":"2023","unstructured":"Wang, T., Tang, Y., Cai, J., et al. (2023). Coadministration of CD19- and CD22-directed chimeric antigen receptor T-cell therapy in childhood B-cell acute lymphoblastic leukemia: A single-arm, multicenter, phase II trial. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol., 41(9), 1670\u20131683.","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"2","key":"10261_CR74","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1182\/blood.2023020621","volume":"143","author":"S Ghorashian","year":"2024","unstructured":"Ghorashian, S., Lucchini, G., Richardson, R., et al. (2024). CD19\/CD22 targeting with cotransduced CAR T cells to prevent antigen-negative relapse after CAR T-cell therapy for B-cell ALL. Blood, 143(2), 118\u2013123.","journal-title":"Blood"},{"issue":"10","key":"10261_CR75","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","volume":"24","author":"M Ruella","year":"2018","unstructured":"Ruella, M., Xu, J., Barrett, D. M., et al. (2018). Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nature Medicine, 24(10), 1499\u20131503.","journal-title":"Nature Medicine"},{"key":"10261_CR76","doi-asserted-by":"crossref","unstructured":"Daher, M., Rezvani, K. (2020) Outlook for new CAR-based therapies with a focus on CAR NK cells: What lies beyond CAR-engineered T cells in the race against cancer. Cancer Discovery.","DOI":"10.1158\/2159-8290.CD-20-0556"},{"issue":"1","key":"10261_CR77","first-page":"64","volume":"9","author":"F You","year":"2019","unstructured":"You, F., Wang, Y., Jiang, L., et al. (2019). A novel CD7 chimeric antigen receptor-modified NK-92MI cell line targeting T-cell acute lymphoblastic leukemia. American Journal of Cancer Research, 9(1), 64\u201378.","journal-title":"American Journal of Cancer Research"},{"issue":"10","key":"10261_CR78","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1038\/leu.2017.8","volume":"31","author":"KH Chen","year":"2017","unstructured":"Chen, K. H., Wada, M., Pinz, K. G., et al. (2017). Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor. Leukemia, 31(10), 2151\u20132160.","journal-title":"Leukemia"},{"issue":"18","key":"10261_CR79","doi-asserted-by":"publisher","first-page":"3853","DOI":"10.1158\/0008-5472.CAN-14-3321","volume":"75","author":"L Poirot","year":"2015","unstructured":"Poirot, L., Philip, B., Schiffer-Mannioui, C., et al. (2015). Multiplex genome-edited T-cell manufacturing platform for \u201coff-the-shelf\u201d adoptive T-cell immunotherapies. Cancer Research, 75(18), 3853\u20133864.","journal-title":"Cancer Research"},{"issue":"7643","key":"10261_CR80","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nature21405","volume":"543","author":"J Eyquem","year":"2017","unstructured":"Eyquem, J., Mansilla-Soto, J., Giavridis, T., et al. (2017). Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection. Nature, 543(7643), 113\u2013117.","journal-title":"Nature"},{"issue":"25","key":"10261_CR81","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1182\/bloodadvances.2017009928","volume":"1","author":"YT Png","year":"2017","unstructured":"Png, Y. T., Vinanica, N., Kamiya, T., et al. (2017). Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies. Blood Advances, 1(25), 2348\u20132360.","journal-title":"Blood Advances"},{"key":"10261_CR82","doi-asserted-by":"crossref","unstructured":"Oh, B. L. Z., Shimasaki, N., Coustan-Smith, E., et al. (2024) Fratricide-resistant CD7-CAR T cells in T-ALL. Nature Medicine","DOI":"10.1038\/s41591-024-03228-8"},{"issue":"3","key":"10261_CR83","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1182\/blood-2017-01-761320","volume":"130","author":"D Gomes-Silva","year":"2017","unstructured":"Gomes-Silva, D., Srinivasan, M., Sharma, S., et al. (2017). CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood, 130(3), 285\u2013296.","journal-title":"Blood"},{"issue":"9","key":"10261_CR84","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1038\/s41375-018-0065-5","volume":"32","author":"ML Cooper","year":"2018","unstructured":"Cooper, M. L., Choi, J., Staser, K., et al. (2018). An \u2018off-the-shelf\u2019 fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies. Leukemia, 32(9), 1970\u20131983.","journal-title":"Leukemia"},{"issue":"6","key":"10261_CR85","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1182\/blood.2022015825","volume":"140","author":"C Diorio","year":"2022","unstructured":"Diorio, C., Murray, R., Naniong, M., et al. (2022). Cytosine base editing enables quadruple-edited allogeneic CART cells for T-ALL. Blood, 140(6), 619\u2013629.","journal-title":"Blood"},{"issue":"4","key":"10261_CR86","first-page":"321","volume":"140","author":"P Lu","year":"2022","unstructured":"Lu, P., Liu, Y., Yang, J., et al. (2022). Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL\/LBL: First-in-human phase 1 clinical trial. Blood, 140(4), 321\u2013334.","journal-title":"Blood"},{"key":"10261_CR87","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.omto.2022.02.013","volume":"24","author":"J Ye","year":"2022","unstructured":"Ye, J., Jia, Y., Tuhin, I. J., et al. (2022). Feasibility study of a novel preparation strategy for anti-CD7 CAR-T cells with a recombinant anti-CD7 blocking antibody. Molecular Theraphy Oncolytics, 24, 719\u2013728.","journal-title":"Molecular Theraphy Oncolytics"},{"issue":"Supplement_1","key":"10261_CR88","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1182\/blood-2019-129559","volume":"134","author":"LC Hill","year":"2019","unstructured":"Hill, L. C., Rouce, R. H., Smith, T. S., et al. (2019). Safety and anti-tumor activity of CD5 CAR T-cells in patients with relapsed\/refractory T-cell malignancies. Blood, 134(Supplement_1), 199\u2013199.","journal-title":"Blood"},{"key":"10261_CR89","doi-asserted-by":"crossref","unstructured":"S\u00e1nchez-Mart\u00ednez, D., Baroni, M. L., Gutierrez-Ag\u00fcera, F., et al. (2019) Fratricide-resistant CD1a-specific CAR T-cells for the treatment of cortical T-cell acute lymphoblastic leukemia. Blood. blood-2018\u201310\u2013882944.","DOI":"10.1182\/blood-2018-10-882944"},{"key":"10261_CR90","doi-asserted-by":"crossref","unstructured":"Maciocia, P. M., Wawrzyniecka, P. A., Maciocia, N. C, et al. (2022) Anti-CCR9 chimeric antigen receptor T cells for T cell acute lymphoblastic leukemia. Blood. blood.2021013648.","DOI":"10.21203\/rs.3.rs-2227661\/v1"},{"issue":"12","key":"10261_CR91","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1038\/nm.4444","volume":"23","author":"PM Maciocia","year":"2017","unstructured":"Maciocia, P. M., Wawrzyniecka, P. A., Philip, B., et al. (2017). Targeting the T cell receptor \u03b2-chain constant region for immunotherapy of T cell malignancies. Nature Medicine, 23(12), 1416\u20131423.","journal-title":"Nature Medicine"},{"issue":"2","key":"10261_CR92","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.cell.2016.09.011","volume":"167","author":"KT Roybal","year":"2016","unstructured":"Roybal, K. T., Williams, J. Z., Morsut, L., et al. (2016). Engineering T cells with customized therapeutic response programs using synthetic notch receptors. Cell, 167(2), 419-432.e16.","journal-title":"Cell"},{"issue":"30","key":"10261_CR93","doi-asserted-by":"publisher","first-page":"3340","DOI":"10.1200\/JCO.21.00389","volume":"39","author":"J Pan","year":"2021","unstructured":"Pan, J., Tan, Y., Wang, G., et al. (2021). Donor-derived CD7 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia: First-in-human, phase I trial. Journal of Clinical Oncology Official Journal of the American Society Clinical Oncology, 39(30), 3340\u20133351.","journal-title":"Journal of Clinical Oncology Official Journal of the American Society Clinical Oncology"},{"key":"10261_CR94","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.3389\/fonc.2019.01358","volume":"9","author":"S Yao","year":"2019","unstructured":"Yao, S., Jianlin, C., Yarong, L., et al. (2019). Donor-derived CD123-targeted CAR T cell serves as a RIC regimen for haploidentical transplantation in a patient with FUS-ERG+ AML. Frontiers in Oncology, 9, 1358.","journal-title":"Frontiers in Oncology"},{"issue":"22","key":"10261_CR95","doi-asserted-by":"publisher","first-page":"3145","DOI":"10.1182\/blood.2020009759","volume":"137","author":"M Wermke","year":"2021","unstructured":"Wermke, M., Kraus, S., Ehninger, A., et al. (2021). Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed\/refractory AML. Blood, 137(22), 3145\u20133148.","journal-title":"Blood"},{"issue":"6","key":"10261_CR96","first-page":"1083","volume":"8","author":"X Tang","year":"2018","unstructured":"Tang, X., Yang, L., Li, Z., et al. (2018). First-in-man clinical trial of CAR NK-92 cells: Safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia. American Journal of Cancer Research, 8(6), 1083\u20131089.","journal-title":"American Journal of Cancer Research"},{"issue":"1","key":"10261_CR97","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/mt.2014.164","volume":"23","author":"Q Wang","year":"2015","unstructured":"Wang, Q., Wang, Y., Lv, H., et al. (2015). Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia. Molecular Theraphy Journal of the American Society Gene Theraphy, 23(1), 184\u2013191.","journal-title":"Molecular Theraphy Journal of the American Society Gene Theraphy"},{"issue":"6","key":"10261_CR98","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1007\/s00277-023-05601-y","volume":"103","author":"X Wang","year":"2024","unstructured":"Wang, X., Zhang, Y., & Xue, S. (2024). Recent progress in chimeric antigen receptor therapy for acute myeloid leukemia. Annals of Hematology, 103(6), 1843\u20131857.","journal-title":"Annals of Hematology"},{"issue":"1","key":"10261_CR99","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13045-021-01092-4","volume":"14","author":"Q Cui","year":"2021","unstructured":"Cui, Q., Qian, C., Xu, N., et al. (2021). CD38-directed CAR-T cell therapy: A novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. Journal Hematology Oncology Journal Hematology Oncology, 14(1), 82.","journal-title":"Journal Hematology Oncology Journal Hematology Oncology"},{"issue":"3","key":"10261_CR100","doi-asserted-by":"publisher","first-page":"e191","DOI":"10.1016\/S2352-3026(22)00378-7","volume":"10","author":"DA Sallman","year":"2023","unstructured":"Sallman, D. A., Kerre, T., Havelange, V., et al. (2023). CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): Haematological cohorts of the dose escalation segment of a phase 1 trial. Lancet Haematol., 10(3), e191\u2013e202.","journal-title":"Lancet Haematol."},{"issue":"1","key":"10261_CR101","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1158\/2326-6066.CIR-18-0307","volume":"7","author":"SH Baumeister","year":"2019","unstructured":"Baumeister, S. H., Murad, J., Werner, L., et al. (2019). Phase I trial of autologous CAR T cells targeting NKG2D ligands in patients with AML\/MDS and multiple myeloma. Cancer Immunology Research, 7(1), 100\u2013112.","journal-title":"Cancer Immunology Research"},{"issue":"2","key":"10261_CR102","doi-asserted-by":"publisher","first-page":"103385","DOI":"10.1016\/j.retram.2023.103385","volume":"71","author":"C Nicod","year":"2023","unstructured":"Nicod, C., da Rocha, M. N., Warda, W., et al. (2023). CAR-T cells targeting IL-1RAP produced in a closed semiautomatic system are ready for the first phase I clinical investigation in humans. Current Research Translational Medicine, 71(2), 103385.","journal-title":"Current Research Translational Medicine"},{"issue":"4","key":"10261_CR103","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/s41591-024-02826-w","volume":"30","author":"G Ghilardi","year":"2024","unstructured":"Ghilardi, G., Fraietta, J. A., Gerson, J. N., et al. (2024). T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy. Nature Medicine, 30(4), 984\u2013989.","journal-title":"Nature Medicine"},{"issue":"13","key":"10261_CR104","doi-asserted-by":"publisher","first-page":"3544","DOI":"10.1182\/bloodadvances.2024013243","volume":"8","author":"AJ Lamble","year":"2024","unstructured":"Lamble, A. J., Schultz, L. M., Nguyen, K., et al. (2024). Risk of T-cell malignancy after CAR T-cell therapy in children, adolescents, and young adults. Blood Advances, 8(13), 3544\u20133548.","journal-title":"Blood Advances"}],"container-title":["Cancer and Metastasis Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-025-10261-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10555-025-10261-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-025-10261-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T10:03:19Z","timestamp":1751018599000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10555-025-10261-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,23]]},"references-count":104,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["10261"],"URL":"https:\/\/doi.org\/10.1007\/s10555-025-10261-7","relation":{},"ISSN":["1573-7233"],"issn-type":[{"value":"1573-7233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,23]]},"assertion":[{"value":"8 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"47"}}